Leukapheresis Market Size, Share & Trends Analysis Report By Product type (Leukapheresis Devices, Centrifugal Devices, Membrane Separators, Leukapheresis Disposables), By Application (Research Application, Therapeutics Application), By End Use (BoldoCenters, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Leukapheresis Market Size & Growth Analysis

The global leukapheresis market size was valued at USD 233.76 million in 2025 and is projected to grow from USD 259.61 million in 2026 to USD 600.88 million by 2034, registering a CAGR of 11.06% during the forecast period from 2026 to 2034. North America dominated the leukapheresis market with a market share of 38.34% in 2025.

The leukapheresis market is structured across product type, application, and end use, reflecting its role in both clinical care and advanced research. By product type, the market includes leukapheresis devices, comprising centrifugal devices and membrane separators, along with leukapheresis disposables that support single-procedure use and procedural consistency. By application, leukapheresis is utilized across research and therapeutics, where research applications include cancer research, immunology research, and other investigative studies requiring high-purity leukocyte collection, while therapeutics applications focus on hematologic disorders, autoimmune diseases, and other clinical indications requiring targeted white blood cell removal or collection. By end use, the market serves blood centers, academic and research institutes, pharmaceutical and biotechnology companies, and hospitals and clinics, with hospitals and clinics acting as primary procedure sites and pharmaceutical and biotechnology companies increasingly leveraging leukapheresis as the initial step in cell and gene therapy development and manufacturing workflows.

Product Type Insights

The leukapheresis devices segment dominated the market in 2025 due to widespread deployment across hospitals and specialized apheresis centers. High utilization of centrifugal devices within therapeutic and cell collection procedures supported sustained demand, as these systems are routinely integrated into oncology and hematology treatment workflows.

The leukapheresis disposables segment is projected to grow at the fastest pace, recording a CAGR of 12.12% during the forecast period. This growth is driven by rising procedure volumes associated with CAR T cell therapy manufacturing and stem cell collection, which require single-use tubing sets, filters, and kits for each procedure, driving recurring consumption.

Request Customizationto receive a tailored report.

Application Insights

The research application segment dominated the leukapheresis market in 2025, supported by extensive use in cancer research and immunology research programs. Academic laboratories and translational research centers increasingly utilize leukapheresis to obtain high-purity leukocyte populations for cell characterization, biomarker discovery, and early-phase therapy development.

The therapeutics application segment is anticipated to grow at the fastest rate, registering a CAGR of 12.45%. Expansion of approved cellular immunotherapies for hematologic disorders and autoimmune diseases has increased the number of leukapheresis procedures performed as a prerequisite for autologous and allogeneic cell therapy production.

End Use Insights

Hospitals and clinics dominated the market in 2025, accounting for 65.12% of total revenue. This dominance is supported by centralized leukapheresis services within tertiary care hospitals that manage high patient volumes across oncology, hematology, and transplant departments.

The pharmaceutical and biotechnology companies segment is projected to grow at the fastest rate, with a CAGR of 12.67%. Growth is driven by the scale-up of clinical trials and commercial manufacturing of cell and gene therapies, where leukapheresis serves as the initial step for patient-specific cell collection used in downstream processing

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America dominated the leukapheresis market in 2025 with a share of 38.34% due to the early commercialization of CAR T cell therapies and the presence of large-scale cell therapy manufacturing infrastructure. High procedural volumes across academic medical centers and oncology hospitals supported steady demand for leukapheresis systems and consumables. Reimbursement coverage for cellular therapies and the expansion of decentralized apheresis centers strengthened procedural adoption across the region.

The U.S. market growth is driven by the concentration of FDA-approved CAR T therapies and the presence of contract development and manufacturing organizations specializing in autologous cell therapies. Increasing clinical trial activity for next-generation gene-modified cell therapies has expanded leukapheresis utilization across research hospitals and commercial treatment centers.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Leukapheresis Market Insights

Asia Pacific is projected to register the fastest growth of 13.06% during the forecast period, supported by rapid expansion of oncology treatment capacity and rising investments in cell and gene therapy infrastructure. Governments across the region are funding translational research programs focused on immuno-oncology, accelerating the adoption of leukapheresis procedures within hospital-based cancer centers.

The China leukapheresis industry is expanding due to the growth of domestic CAR T developers and increasing regulatory approvals for locally manufactured cell therapies. Hospital networks are investing in apheresis equipment to support both clinical trials and commercial-scale cell collection activities.

Europe Market Insights

Europe demonstrates steady market growth driven by cross-border collaboration in cellular therapy research and harmonized regulatory pathways for advanced therapy medicinal products. Public health systems are integrating leukapheresis services within specialized hematology and transplant centers, supporting consistent procedural demand.

The Germany market benefits from a strong stem cell transplantation ecosystem and government-backed funding for immunotherapy research. The presence of specialized apheresis centers supporting both therapeutic leukapheresis and cell collection for manufacturing activities contributes to market expansion.

Latin America Market Insights

Latin America is witnessing gradual growth as tertiary care hospitals expand hematology oncology services and adopt advanced blood separation technologies. Regional demand is supported by increasing awareness of therapeutic leukapheresis for hematologic disorders and early-stage adoption of cellular therapies.

The Brazil leukapheresis market is driven by investments in public cancer institutes and the development of domestic cell therapy research programs. Collaboration between academic institutions and government research bodies is increasing access to leukapheresis procedures.

Middle East and Africa Market Insights

The Middle East and Africa market is expanding at a measured pace due to the gradual modernization of oncology treatment infrastructure and the selective adoption of advanced apheresis technologies. Demand is concentrated in specialized hospitals offering hematology and transplant services.

The Saudi Arabia market growth is supported by national healthcare transformation initiatives focused on expanding advanced cancer treatment services. Investment in specialty hospitals and medical cities is increasing access to leukapheresis procedures for complex hematologic indications.

Competitive Landscape:

The leukapheresis market is moderately competitive, with a mix of multinational medical technology companies and specialized apheresis solution providers holding notable market share.

• Miltenyi Biotec: An emerging market player

Miltenyi Biotec is gaining attention as an emerging player in the market due to its expanding focus on cell collection and processing solutions aligned with advanced cell and gene therapy workflows. The company emphasizes integrated systems that combine leukapheresis-compatible cell separation, enrichment technologies, and closed system processing to support autologous and allogeneic therapies. Its growing collaboration with academic research centers, biotechnology firms, and clinical manufacturing facilities strengthens its positioning alongside established leukapheresis providers. By concentrating on scalable platforms, standardized consumables, and regulatory-compliant solutions, Miltenyi Biotec is steadily expanding its footprint in clinical and commercial cell therapy-driven leukapheresis applications.

List of Key and Emerging Players in Leukapheresis Market